Product Description
Mechanisms of Action: KSP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Paranasal Sinus Diseases|Head and Neck Cancer|Colorectal Cancer|Ovarian Cancer|Breast Cancer|Adenocarcinoma|Salivary Gland Diseases|Oropharyngeal Cancer|Squamous Cell Carcinoma|Prostate Cancer|Laryngeal Cancer|Paranasal Sinus Cancer|Verrucous Carcinoma|Salivary Gland Cancer|Liver Cancer|Non-Small-Cell Lung Cancer|Renal Cell Carcinoma|Melanoma
Phase 1: Acute Myeloid Leukemia|Preleukemia|Acute Megakaryoblastic Leukemia|Myelodysplastic Syndrome|Oncology Solid Tumor Unspecified|Chronic Myeloid Leukemia|Anemia, Refractory, with Excess of Blasts|Breast Cancer|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Chronic Lymphoid Leukemia|Acute Monocytic Leukemia|Chronic Myelomonocytic Leukemia|Acute Promyelocytic Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Blast Crisis|Acute Myelomonocytic Leukemia|Acute Lymphoid Leukemia|Acute Erythroblastic Leukemia|Ependymoma|Adamantinoma|Meningioma|Lymphomatoid Granulomatosis|Burkitt Lymphoma|Lymphoma, Non-Hodgkin|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Craniopharyngioma|Astrocytoma|Lymphoid Leukemia|Optic Nerve Glioma|T-Cell Leukemia|Primitive Neuroectodermal Tumors|Medulloblastoma|Brain Stem Cancer|Primary Central Nervous System Lymphoma|Extranodal NK-T-Cell Lymphoma|B-Cell Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia|Leukemia, Plasma Cell|Hodgkin Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Mantle-Cell Lymphoma|Follicular Lymphoma|Adult T-Cell Leukemia-Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Large-Cell Immunoblastic Lymphoma|Diffuse Large B-Cell Lymphoma|Plasmablastic Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCI-2012-03091 | P2 |
Completed |
Head and Neck Cancer|Paranasal Sinus Diseases|Salivary Gland Diseases|Laryngeal Cancer|Paranasal Sinus Cancer|Salivary Gland Cancer|Verrucous Carcinoma|Oropharyngeal Cancer|Squamous Cell Carcinoma |
2010-07-01 |
|
| NCI-2012-03193 | P1 |
Terminated |
Waldenstrom Macroglobulinemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Extranodal NK-T-Cell Lymphoma|Mantle-Cell Lymphoma|Hodgkin Lymphoma|Lymphomatoid Granulomatosis|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|B-Cell Marginal Zone Lymphoma|Adult T-Cell Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, Non-Hodgkin|Diffuse Large B-Cell Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Large-Cell Immunoblastic Lymphoma|Leukemia, Plasma Cell|Plasmablastic Lymphoma|Chronic Lymphoid Leukemia|Follicular Lymphoma|Burkitt Lymphoma |
2010-02-01 |
|
| NCI-2012-02834 | P2 |
Completed |
Colorectal Cancer |
2010-01-01 |
|
| CY 3121 | P1 |
Terminated |
Breast Cancer |
2009-11-01 |
42% |